Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

6262 ARTÍCULOS , VIENDO DEL 4951 AL 4965

Epigenetic Orchestration of Neurodegenerative Disorders: A Possible Target for Curcumin as a Therapeutic

Tripathi S, Bhawana.

Neurochem Res. 2024 Sep;49(9):2319-2335. doi: 10.1007/s11064-024-04167-z. Epub 2024 Jun 10.

Childhood-onset Huntignton´s disease. A rare presentation

Gauto A, Bellantonio E, Pedernera-Bradichansky P, Cafiero P, Rodriguez E, Massaro P.

Rev Neurol. 2024 Mar 1;78(5):135-138. doi: 10.33588/rn.7805.2024039.

Advancements in Targeting Ion Channels for the Treatment of Neurodegenerative Diseases

Li Y, Fu J, Wang H.

Pharmaceuticals (Basel). 2024 Oct 31;17(11):1462. doi: 10.3390/ph17111462.

New perspective on central nervous system disorders: focus on mass spectrometry imaging

Lai H, Fan P, Wang H, Wang Z, Chen N.

Anal Methods. 2024 Dec 5;16(47):8080-8102. doi: 10.1039/d4ay01205d.

Sesamol: A Phenolic Compound of Health Benefits and Therapeutic Promise in Neurodegenerative Diseases

Javed H, Meeran MFN, Jha NK, Ashraf GM, Ojha S.

Curr Top Med Chem. 2024;24(9):797-809. doi: 10.2174/0115680266273944231213070916.

Diagnostics and Management Challenges of Nonpuerperal Uterine Inversions - Case Series

Sasotya RMS, Rinaldi A, Achmad ED, Ma'soem AP, Praharsini K, Imantika E, Wulandari F, Nathania N, Tjandraprawira KD.

Int J Womens Health. 2024 Aug 27;16:1425-1435. doi: 10.2147/IJWH.S474778. eCollection 2024.

Presymptomatic Targeted Circuit Manipulation for Ameliorating Huntington's Disease Pathogenesis

Ikefuama EC, Slaviero AN, Schalau R, Gott M, Tree MO, Dunbar GL, Rossignol J, Hochgeschwender U.

bioRxiv [Preprint]. 2024 Jul 24:2024.07.24.604946. doi: 10.1101/2024.07.24.604946.

Medication Use and Treatment Indications in Huntington's Disease; Analyses from a Large Cohort

Feleus S, Skotnicki LEM, Roos RAC, de Bot ST.

Mov Disord Clin Pract. 2024 Dec;11(12):1530-1541. doi: 10.1002/mdc3.14230. Epub 2024 Oct 21.

Trial to assess the tolerability of using felodipine to upregulate autophagy as a treatment of Huntington's disease (FELL-HD): a phase II, single-centre, open-label, dose-finding trial protocol

Andresen K, Cutting E, Apostolopoulos D, Evans AH, Oakley L, Dayimu A, Demiris N, Bongaerts K, Staples R, Gooding W, Rubinsztein D, Barker RA.

BMJ Open. 2024 Aug 21;14(8):e087983. doi: 10.1136/bmjopen-2024-087983.

Decoding mitochondrial quality control mechanisms: Identifying treatment targets for enhanced cellular health

Wankhede NL, Rajendra Kopalli S, Dhokne MD, Badnag DJ, Chandurkar PA, Mangrulkar SV, Shende PV, Taksande BG, Upaganlawar AB, Umekar MJ, Koppula S, Kale MB.

Mitochondrion. 2024 Sep;78:101926. doi: 10.1016/j.mito.2024.101926. Epub 2024 Jun 27.

Advances in iPSC Technology in Neural Disease Modeling, Drug Screening, and Therapy

Dai S, Qiu L, Veeraraghavan VP, Sheu CL, Mony U.

Curr Stem Cell Res Ther. 2024;19(6):809-819. doi: 10.2174/1574888X18666230608105703.

Current Overview on the Use of Nanosized Drug Delivery Systems in the Treatment of Neurodegenerative Diseases

Ozceylan O, Sezgin-Bayindir Z.

ACS Omega. 2024 Aug 5;9(33):35223-35242. doi: 10.1021/acsomega.4c01774. eCollection 2024 Aug 20.

Protocol for a randomised controlled unblinded feasibility trial of HD-DRUM: a rhythmic movement training application for cognitive and motor symptoms in people with Huntington's disease

Ioakeimidis V, Busse M, Drew CJG, Pallmann P, Watson GB, Jones D, Palombo M, Schubert R, Rosser AE, Metzler-Baddeley C.

BMJ Open. 2024 Jul 31;14(7):e082161. doi: 10.1136/bmjopen-2023-082161.

The Multifaceted Role of Cofilin in Neurodegeneration and Stroke: Insights into Pathogenesis and Targeting as a Therapy

Shehjar F, Almarghalani DA, Mahajan R, Hasan SA, Shah ZA.

Cells. 2024 Jan 18;13(2):188. doi: 10.3390/cells13020188.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias